Oncofetal Biology: From Fundamental Mechanisms to Emerging Therapeutic Opportunities

Abstract

The parallels between embryonic development and tumorigenesis have reshaped how we conceptualize cancer's molecular foundations. Once viewed as purely mutation-driven, malignancy is now understood to involve the systematic reactivation of embryonic gene programs—raising a fundamental question: How extensively do tumors co-opt developmental machinery to sustain their aggressive phenotypes? This review provides a comprehensive synthesis integrating developmental biology, reproductive medicine, and molecular oncology. It systematically examines how tumor cells exploit core developmental machinery, including pluripotency maintenance networks, evolutionarily conserved signaling pathways and epigenetic reprogramming mechanisms, such as DNA methylation, histone modifications, and non-coding RNA regulation, to acquire stemness properties, drive epithelial-mesenchymal transition (EMT), remodel the extracellular matrix (ECM), and establish immunosuppressive microenvironments. We further explore germ cell tumor biology, assisted reproductive technology (ART) implications, and DNA damage response vulnerabilities from a developmental perspective. These molecular insights furnish tangible opportunities: biomarker discovery rooted in fetal antigen re-expression, and therapeutic strategies that selectively disrupt the “embryonic” state of cancer cells while sparing normal tissue. This review synthesizes the core molecular mechanisms connecting embryonic development and tumorigenesis from a multidisciplinary standpoint and outlines future research trajectories and clinical applications, thereby contributing new insights and actionable strategies in the fight against cancer.

Keywords

cancer stem cells / embryonic development / epigenetic reprogramming / oncofetal biology / tumorigenesis

References

[1] S. L. Miller, “A Production of Amino Acids Under Possible Primitive Earth Conditions,” Science 117, no. 3046 (1953): 528–529.

[2] M. N. Shahbazi, E. D. Siggia, and M. Zernicka-Goetz, “Self-Organization of Stem Cells Into Embryos: A Window on Early Mammalian Development,” Science 364, no. 6444 (2019): 948–951.

[3] C. Nüsslein-Volhard and E. Wieschaus, “Mutations Affecting Segment Number and Polarity in Drosophila,” Nature 287, no. 5785 (1980): 795–801.

[4] K. Hardy, A. H. Handyside, and R. M. L. Winston, “The Human Blastocyst: Cell Number, Death and Allocation During Late Preimplantation Development In Vitro,” Development 107, no. 3 (1989): 597–604.

[5] R. Demir, Y. Seval, and B. Huppertz, “Vasculogenesis and Angiogenesis in the Early Human Placenta,” Acta Histochemica 109, no. 4 (2007): 257–265.

[6] D. Hanahan and R. A. Weinberg, “The Hallmarks of Cancer,” Cell 100, no. 1 (2000): 57–70.

[7] C. Tomasetti and B. Vogelstein, “Variation in Cancer Risk Among Tissues Can be Explained by the Number of Stem Cell Divisions,” Science 347, no. 6217 (2015): 78–81.

[8] I. Ben-Porath, M. W. Thomson, V. J. Carey, et al., “An Embryonic Stem Cell-Like Gene Expression Signature in Poorly Differentiated Aggressive Human Tumors,” Nature Genetics 40, no. 5 (2008): 499–507.

[9] M. Vincent, “Cancer: A De-Repression of a Default Survival Program Common to All Cells?: A Life-History Perspective on the Nature of Cancer,” BioEssays 34, no. 1 (2012): 72–82.

[10] P. C. W. Davies and C. H. Lineweaver, “Cancer Tumors as Metazoa 1.0: Tapping Genes of Ancient Ancestors,” Physical Biology 8, no. 1 (2011): 015001.

[11] K. Hammerschmidt, C. J. Rose, B. Kerr, and P. B. Rainey, “Life Cycles, Fitness Decoupling and the Evolution of Multicellularity,” Nature 515, no. 7525 (2014): 75–79.

[12] T. Domazet-Loso and D. Tautz, “Phylostratigraphic Tracking of Cancer Genes Suggests a Link to the Emergence of Multicellularity in Metazoa,” BMC Biology 8 (2010): 66.

[13] D. Hanahan and R. A. Weinberg, “Hallmarks of Cancer: The Next Generation,” Cell 144, no. 5 (2011): 646–674.

[14] J. A. Joyce and J. W. Pollard, “Microenvironmental Regulation of Metastasis,” Nature Reviews Cancer 9, no. 4 (2009): 239–252.

[15] H. Clevers, “The Cancer Stem Cell: Premises, Promises and Challenges,” Nature Medicine 17, no. 3 (2011): 313–319.

[16] A. Sharma, C. Blériot, J. Currenti, and F. Ginhoux, “Oncofetal Reprogramming in Tumour Development and Progression,” Nature Reviews Cancer 22, no. 10 (2022): 593–602.

[17] S. Sell and G. B. Pierce, “Maturation Arrest of Stem Cell Differentiation Is a Common Pathway for the Cellular Origin of Teratocarcinomas and Epithelial Cancers,” Laboratory Investigation; A Journal of Technical Methods and Pathology 70, no. 1 (1994): 6–22.

[18] J. P. Thiery, H. Acloque, R. Y. J. Huang, and M. A. Nieto, “Epithelial-Mesenchymal Transitions in Development and Disease,” Cell 139, no. 5 (2009): 871–890.

[19] M. A. Nieto, R. Y. J. Huang, R. A. Jackson, and J. P. Thiery, “EMT: 2016,” Cell 166, no. 1 (2016): 21–45.

[20] L. C. Stevens, “The Biology of Teratomas,” Advances in Morphogenesis 6 (1967): 1–31.

[21] J. W. Oosterhuis and L. H. J. Looijenga, “Testicular Germ-Cell Tumours in a Broader Perspective,” Nature Reviews Cancer 5, no. 3 (2005): 210–222.

[22] A. P. Feinberg, R. Ohlsson, and S. Henikoff, “The Epigenetic Progenitor Origin of Human Cancer,” Nature Reviews Genetics 7, no. 1 (2006): 21–33.

[23] S. Mzoughi, M. Schwarz, X. Wang, et al., “Oncofetal Reprogramming Drives Phenotypic Plasticity in WNT-Dependent Colorectal Cancer,” Nature Genetics 57, no. 2 (2025): 402–412.

[24] A. Pierani, C. Pouponnot, and G. Calothy, “Developmental Control of Transcription of a Retina-Specific Gene, QR1, During Differentiation: Involvement of Factors From the POU Family,” Molecular and Cellular Biology 15, no. 2 (1995): 642–652.

[25] S. J. Arnold and E. J. Robertson, “Making a Commitment: Cell Lineage Allocation and Axis Patterning in the Early Mouse Embryo,” Nature Reviews Molecular Cell Biology 10, no. 2 (2009): 91–103.

[26] J. Rossant and P. P. L. Tam, “Blastocyst Lineage Formation, Early Embryonic Asymmetries and Axis Patterning in the Mouse,” Development 136, no. 5 (2009): 701–713.

[27] M. J. Evans and M. H. Kaufman, “Establishment in Culture of Pluripotential Cells From Mouse Embryos,” Nature 292, no. 5819 (1981): 154–156.

[28] Z. Wang, E. Oron, B. Nelson, S. Razis, and N. Ivanova, “Distinct Lineage Specification Roles for NANOG, OCT4, and SOX2 in Human Embryonic Stem Cells,” Cell Stem Cell 10, no. 4 (2012): 440–454.

[29] K. Takahashi, K. Tanabe, M. Ohnuki, et al., “Induction of Pluripotent Stem Cells From Adult Human Fibroblasts by Defined Factors,” Cell 131, no. 5 (2007): 861–872.

[30] J. Yu, M. A. Vodyanik, K. Smuga-Otto, et al., “Induced Pluripotent Stem Cell Lines Derived From Human Somatic Cells,” Science 318, no. 5858 (2007): 1917–1920.

[31] D. Wei, M. Kanai, S. Huang, and K. Xie, “Emerging Role of KLF4 in Human Gastrointestinal Cancer,” Carcinogenesis 27, no. 1 (2006): 23–31.

[32] C. V. Dang, “Myc on the Path to Cancer,” Cell 149, no. 1 (2012): 22–35.

[33] S. R. Viswanathan, G. Q. Daley, and R. I. Gregory, “Selective Blockade of microRNA Processing by Lin28,” Science 320, no. 5872 (2008): 97–100.

[34] J. E. Visvader and G. J. Lindeman, “Cancer Stem Cells in Solid Tumours: Accumulating Evidence and Unresolved Questions,” Nature Reviews Cancer 8, no. 10 (2008): 755–768.

[35] M. L. Suvà, N. Riggi, and B. E. Bernstein, “Epigenetic Reprogramming in Cancer,” Science 339, no. 6127 (2013): 1567–1570.

[36] M. V. Shaikh, S. Custers, A. Anand, P. Miletic, C. Venugopal, and S. K. Singh, “Cancer Stem Cells: Current Challenges and Future Perspectives,” Methods in Molecular Biology 2777 (2024): 1–18.

[37] G. C. Nwokolo, T. S. Ganesan, K. Pors, R. A. Falconer, and S. Smarakan, “Cancer Stem Cells in Focus: Deciphering the Dynamic Functional Landscape of Stemness in Cancer,” Biochimica et Biophysica Acta (BBA)—Reviews on Cancer 1880, no. 5 (2025): 189440.

[38] G. Q. Ling, D. B. Chen, B. Q. Wang, and L. S. Zhang, “Expression of the Pluripotency Markers Oct3/4, Nanog and Sox2 in Human Breast Cancer Cell Lines,” Oncology Letters 4, no. 6 (2012): 1264–1268.

[39] M. E. Shaul and Z. G. Fridlender, “Tumour-Associated Neutrophils in Patients With Cancer,” Nature Reviews Clinical Oncology 16, no. 10 (2019): 601–620.

[40] C. V. Dang, “Links Between Metabolism and Cancer,” Genes & Development 26, no. 9 (2012): 877–890.

[41] K. Takahashi and S. Yamanaka, “A Decade of Transcription Factor-Mediated Reprogramming to Pluripotency,” Nature Reviews Molecular Cell Biology 17, no. 3 (2016): 183–193.

[42] T. Wei, R. Lin, X. Fu, et al., “Epigenetic Regulation of the DNMT1/MT1G/KLF4/CA9 Axis Synergises the Anticancer Effects of Sorafenib in Hepatocellular Carcinoma,” Pharmacological Research 180 (2022): 106244.

[43] A. Merve, X. Zhang, N. Pomella, et al., “c-MYC Overexpression Induces Choroid Plexus Papillomas Through a T-Cell Mediated Inflammatory Mechanism,” Acta Neuropathologica Communications 7, no. 1 (2019): 95.

[44] F. Wu, J. Yang, J. Liu, et al., “Signaling Pathways in Cancer-Associated Fibroblasts and Targeted Therapy for Cancer,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 218.

[45] J. Massagué, “TGFβ Signalling in Context,” Nature Reviews Molecular Cell Biology 13, no. 10 (2012): 616–630.

[46] B. Dietrich, S. Haider, G. Meinhardt, J. Pollheimer, and M. Knöfler, “WNT and NOTCH Signaling in Human Trophoblast Development and Differentiation,” Cellular and Molecular Life Sciences 79, no. 6 (2022): 292.

[47] O. Dreesen and A. H. Brivanlou, “Signaling Pathways in Cancer and Embryonic Stem Cells,” Stem Cell Reviews 3, no. 1 (2007): 7–17.

[48] J. J. Loh and S. Ma, “Hallmarks of Cancer Stemness,” Cell Stem Cell 31, no. 5 (2024): 617–639.

[49] J. A. Thomson, J. Itskovitz-Eldor, S. S. Shapiro, et al., “Embryonic Stem Cell Lines Derived From Human Blastocysts,” Science 282, no. 5391 (1998): 1145–1147.

[50] Q. Yan, X. Fang, C. Li, P. Lan, and X. Guan, “Oncofetal Proteins and Cancer Stem Cells,” Essays in Biochemistry 66, no. 4 (2022): 423–433.

[51] M. Erkisa, D. Karakas, and E. Ulukaya, “Cancer Stem Cells: Root of the Evil,” Critical Reviews in Oncogenesis 24, no. 1 (2019): 69–87.

[52] I. Chambers, D. Colby, M. Robertson, et al., “Functional Expression Cloning of Nanog, a Pluripotency Sustaining Factor in Embryonic Stem Cells,” Cell 113, no. 5 (2003): 643–655.

[53] L. A. Boyer, T. I. Lee, M. F. Cole, et al., “Core Transcriptional Regulatory Circuitry in Human Embryonic Stem Cells,” Cell 122, no. 6 (2005): 947–956.

[54] T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, “Stem Cells, Cancer, and Cancer Stem Cells,” Nature 414, no. 6859 (2001): 105–111.

[55] N. Takebe, L. Miele, P. J. Harris, et al., “Targeting Notch, Hedgehog, and Wnt Pathways in Cancer Stem Cells: Clinical Update,” Nature Reviews Clinical Oncology 12, no. 8 (2015): 445–464.

[56] H. Clevers, “Wnt/β-Catenin Signaling in Development and Disease,” Cell 127, no. 3 (2006): 469–480.

[57] J. Liu, C. Sato, M. Cerletti, and A. Wagers, “Notch Signaling in the Regulation of Stem Cell Self-Renewal and Differentiation,” Current Topics in Developmental Biology 92 (2010): 367–409.

[58] S. Sharma, T. K. Kelly, and P. A. Jones, “Epigenetics in Cancer,” Carcinogenesis 31, no. 1 (2010): 27–36.

[59] A. P. Feinberg, M. A. Koldobskiy, and A. Göndör, “Epigenetic Modulators, Modifiers and Mediators in Cancer Aetiology and Progression,” Nature Reviews Genetics 17, no. 5 (2016): 284–299.

[60] M. F. Clarke, J. E. Dick, P. B. Dirks, et al., “Cancer Stem Cells--Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells,” Cancer Research 66, no. 19 (2006): 9339–9344.

[61] H. Clevers and F. M. Watt, “Defining Adult Stem Cells by Function, Not by Phenotype,” Annual Review of Biochemistry 87 (2018): 1015–1027.

[62] H. Clevers, “Modeling Development and Disease With Organoids,” Cell 165, no. 7 (2016): 1586–1597.

[63] C. Blanpain and E. Fuchs, “Epidermal Homeostasis: A Balancing Act of Stem Cells in the Skin,” Nature Reviews Molecular Cell Biology 10, no. 3 (2009): 207–217.

[64] B. Vogelstein, N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz,., and K. W. Kinzler, “Cancer Genome Landscapes,” Science 339, no. 6127 (2013): 1546–1558.

[65] O. Shalem, N. E. Sanjana, and F. Zhang, “High-Throughput Functional Genomics Using CRISPR-Cas9,” Nature Reviews Genetics 16, no. 5 (2015): 299–311.

[66] B. E. Richardson and R. Lehmann, “Mechanisms Guiding Primordial Germ Cell Migration: Strategies From Different Organisms,” Nature Reviews Molecular Cell Biology 11, no. 1 (2010): 37–49.

[67] M. De Felici, “The Formation and Migration of Primordial Germ Cells in Mouse and Man,” Results and Problems in Cell Differentiation 58 (2016): 23–46.

[68] F. Bulic-Jakus, A. Katusic Bojanac, G. Juric-Lekic, M. Vlahovic, and N. Sincic, “Teratoma: From Spontaneous Tumors to the Pluripotency/Malignancy Assay,” WIREs Developmental Biology 5, no. 2 (2016): 186–209.

[69] K. E. Shopsowitz, X. Q. Wang, M. Soleimani, M. Hudoba, L. Y. C. Chen, and E. McGinnis, “Metastatic Seminoma Masquerading as Sarcoidosis,” Lancet Oncology 24, no. 8 (2023): e355.

[70] M. De Felici and S. Dolci, “In Vitro Adhesion of Mouse Fetal Germ Cells to Extracellular Matrix Components,” Cell Differentiation and Development 26, no. 2 (1989): 87–96.

[71] N. Singla, A. Bagrodia, E. Baraban, C. D. Fankhauser, and Y. M. A. Ged, “Testicular Germ Cell Tumors: A Review,” Journal of the American Medical Association 333, no. 9 (2025): 793–803.

[72] A. Horwich, J. Shipley, and R. Huddart, “Testicular Germ-Cell Cancer,” Lancet 367, no. 9512 (2006): 754–765.

[73] Z. Du, K. Zhang, and W. Xie, “Epigenetic Reprogramming in Early Animal Development,” Cold Spring Harbor Perspectives in Biology 14, no. 6 (2022): a039677.

[74] S. Seisenberger, J. R. Peat, T. A. Hore, F. Santos, W. Dean, and W. Reik, “Reprogramming DNA Methylation in the Mammalian Life Cycle: Building and Breaking Epigenetic Barriers,” Philosophical Transactions of the Royal Society, B: Biological Sciences 368, no. 1609 (2013): 20110330.

[75] G. J. Netto, Y. Nakai, M. Nakayama, et al., “Global DNA Hypomethylation in Intratubular Germ Cell Neoplasia and Seminoma, but Not in Nonseminomatous Male Germ Cell Tumors,” Modern Pathology 21, no. 11 (2008): 1337–1344.

[76] N. Singh, D. Baby, J. Rajguru, P. Patil, S. Thakkannavar, and V. Pujari, “Inflammation and Cancer,” Annals of African Medicine 18, no. 3 (2019): 121–126.

[77] E. R. Norwitz, D. J. Schust, and S. J. Fisher, “Implantation and the Survival of Early Pregnancy,” New England Journal of Medicine 345, no. 19 (2001): 1400–1408.

[78] K. Red-Horse, Y. Zhou, O. Genbacev, et al., “Trophoblast Differentiation During Embryo Implantation and Formation of the Maternal-Fetal Interface,” Journal of Clinical Investigation 114, no. 6 (2004): 744–754.

[79] U. Hiden, M. Bilban, M. Knöfler, and G. Desoye, “Kisspeptins and the Placenta: Regulation of Trophoblast Invasion,” Reviews in Endocrine & Metabolic Disorders 8, no. 1 (2007): 31–39.

[80] R. D. Owen, “Immunogenetic Consequences of Vascular Anastomoses Between Bovine Twins,” Science 102, no. 2651 (1945): 400–401.

[81] P. Srivastava, “Roles of Heat-Shock Proteins in Innate and Adaptive Immunity,” Nature Reviews Immunology 2, no. 3 (2002): 185–194.

[82] A. M. Heeren, S. Punt, M. C. Bleeker, et al., “Prognostic Effect of Different PD-L1 Expression Patterns in Squamous Cell Carcinoma and Adenocarcinoma of the Cervix,” Modern Pathology 29, no. 7 (2016): 753–763.

[83] N. Auersperg, N. Auersperg, A. S. T. Wong, K. C. Choi, S. K. Kang, and P. C. K. Leung, “Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology,” Endocrine Reviews 22, no. 2 (2001): 255–288.

[84] J. V. Bokhman, “Two Pathogenetic Types of Endometrial Carcinoma,” Gynecologic Oncology 15, no. 1 (1983): 10–17.

[85] A. N. Andersen, L. Gianaroli, R. Felberbaum, J. de Mouzon, and K. G. Nygren, “Assisted Reproductive Technology in Europe, 2001. Results Generated From European Registers by ESHRE,” Human Reproduction 20, no. 5 (2005): 1158–1176.

[86] P. Rios, P. Herlemont, P. Fauque, et al., “Medically Assisted Reproduction and Risk of Cancer Among Offspring,” JAMA Network Open 7, no. 5 (2024): e249429.

[87] K. J. Sundh, A. K. A. Henningsen, K. Kallen, et al., “Cancer in Children and Young Adults Born After Assisted Reproductive Technology: A Nordic Cohort Study From the Committee of Nordic ART and Safety (CoNARTaS),” Human Reproduction 29, no. 9 (2014): 2050–2057.

[88] P. E. Levi-Setti and P. Patrizio, “Assisted Reproductive Technologies (ART) and Childhood Cancer: Is the Risk Real?,” Journal of Assisted Reproduction and Genetics 35, no. 10 (2018): 1773–1775.

[89] N. Sargisian, B. Lannering, M. Petzold, et al., “Cancer in Children Born After Frozen-Thawed Embryo Transfer: A Cohort Study,” PLoS Medicine 19, no. 9 (2022): e1004078.

[90] J. Huntriss and H. M. Picton, “Stability of Genomic Imprinting in Embryonic Stem Cells: Lessons From Assisted Reproductive Technology,” Current stem cell research & therapy 3, no. 2 (2008): 107–116.

[91] R. Sciorio, L. Tramontano, G. Gullo, and S. Fleming, “Association Between Human Embryo Culture Conditions, Cryopreservation, and the Potential Risk of Birth Defects in Children Conceived Through Assisted Reproduction Technology,” Medicina 61, no. 7 (2025): 1194.

[92] E. Lanphier, F. Urnov, S. E. Haecker, M. Werner, and J. Smolenski, “Don't Edit the Human Germ Line,” Nature 519, no. 7544 (2015): 410–411.

[93] A. Maheshwari, V. Bari, J. L. Bell, et al., “Transfer of Thawed Frozen Embryo Versus Fresh Embryo to Improve the Healthy Baby Rate in Women Undergoing IVF: The E-Freeze RCT,” Health Technology Assessment 26, no. 25 (2022): 1–142.

[94] R. Gonzalez-Exposito, M. Merino, and C. Aguayo, “Molecular Biology of Testicular Germ Cell Tumors,” Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 18, no. 6 (2016): 550–556.

[95] Y. Mizobe, N. Oya, R. Iwakiri, et al., “Effects of Early Cleavage Patterns of Human Embryos on Subsequent In Vitro Development and Implantation,” Fertility and Sterility 106, no. 2 (2016): 348–353.e2.

[96] M. Spaan, A. W. van den Belt-Dusebout, M. M. van den Heuvel-Eibrink, et al., “Risk of Cancer in Children and Young Adults Conceived by Assisted Reproductive Technology,” Human Reproduction 34, no. 4 (2019): 740–750.

[97] D. Gilboa, G. Koren, Y. Barer, et al., “Assisted Reproductive Technology and the Risk of Pediatric Cancer: A Population Based Study and a Systematic Review and Meta Analysis,” Cancer Epidemiology 63 (2019): 101613.

[98] S. J. Lee, L. R. Schover, A. H. Partridge, et al., “American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients,” Journal of Clinical Oncology 24, no. 18 (2006): 2917–2931.

[99] N. Spears, F. Lopes, A. Stefansdottir, et al., “Ovarian Damage From Chemotherapy and Current Approaches to Its Protection,” Human Reproduction Update 25, no. 6 (2019): 673–693.

[100] M. I. Albamonte and A. D. Vitullo, “Preservation of Fertility in Female and Male Prepubertal Patients Diagnosed With Cancer,” Journal of Assisted Reproduction and Genetics 40, no. 12 (2023): 2755–2767.

[101] R. Xu, Y. Li, Y. Wu, X. Liu, and S. Gao, “Epigenetic Regulation in Early Embryo Development: From Zygotic Genome Activation to the First Lineage Specification,” Trends in Genetics 41, no. 10 (2025): 899–918.

[102] L. Yang, R. Rau, and M. A. Goodell, “DNMT3A in Haematological Malignancies,” Nature Reviews Cancer 15, no. 3 (2015): 152–165.

[103] W. Reik, W. Dean, and J. Walter, “Epigenetic Reprogramming in Mammalian Development,” Science 293, no. 5532 (2001): 1089–1093.

[104] L. Sun, H. Zhang, and P. Gao, “Metabolic Reprogramming and Epigenetic Modifications on the Path to Cancer,” Protein & Cell 13, no. 12 (2022): 877–919.

[105] E. M. Michalak, M. L. Burr, A. J. Bannister, and M. A. Dawson, “The Roles of DNA, RNA and Histone Methylation in Ageing and Cancer,” Nature Reviews Molecular Cell Biology 20, no. 10 (2019): 573–589.

[106] L. Li, X. Fei, H. Wang, et al., “Genome-Wide DNA Methylation Profiling Reveals a Novel Hypermethylated Biomarker PRKCB in Gastric Cancer,” Scientific Reports 14, no. 1 (2024): 26605.

[107] F. D. E. De Palma, J. G. Pol, V. Carbonnier, et al., “Epigenetic Regulation of HOXA2 Expression Affects Tumor Progression and Predicts Breast Cancer Patient Survival,” Cell Death & Differentiation 32, no. 4 (2025): 730–744.

[108] S. Tommasi, D. L. Karm, X. Wu, Y. Yen, and G. P. Pfeifer, “Methylation of Homeobox Genes Is a Frequent and Early Epigenetic Event in Breast Cancer,” Breast Cancer Research 11, no. 1 (2009): R14.

[109] G. Egger, G. Liang, A. Aparicio, and P. A. Jones, “Epigenetics in Human Disease and Prospects for Epigenetic Therapy,” Nature 429, no. 6990 (2004): 457–463.

[110] M. Sébert, A. Renneville, C. Bally, et al., “A Phase II Study of Guadecitabine in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia After Azacitidine Failure,” Haematologica 104, no. 8 (2019): 1565–1571.

[111] M. F. Lofiego, R. Tufano, E. Bello, et al., “DNA Methylation Status Classifies Pleural Mesothelioma Cells According to Their Immune Profile: Implication for Precision Epigenetic Therapy,” Journal of Experimental & Clinical Cancer Research 44, no. 1 (2025): 58.

[112] T. Kouzarides, “Chromatin Modifications and Their Function,” Cell 128, no. 4 (2007): 693–705.

[113] S. L. Berger, “The Complex Language of Chromatin Regulation During Transcription,” Nature 447, no. 7143 (2007): 407–412.

[114] T. I. Lee and R. A. Young, “Transcriptional Regulation and Its Misregulation in Disease,” Cell 152, no. 6 (2013): 1237–1251.

[115] R. Nirmaladevi, “Epigenetic Alterations in Cancer,” Frontiers in Bioscience 25, no. 6 (2020): 1058–1109.

[116] P. A. Marks, V. M. Richon, and R. A. Rifkind, “Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells,” JNCI Journal of the National Cancer Institute 92, no. 15 (2000): 1210–1216.

[117] S. Varambally, S. M. Dhanasekaran, M. Zhou, et al., “The Polycomb Group Protein EZH2 Is Involved in Progression of Prostate Cancer,” Nature 419, no. 6907 (2002): 624–629.

[118] J. A. Simon and R. E. Kingston, “Occupying Chromatin: Polycomb Mechanisms for Getting to Genomic Targets, Stopping Transcriptional Traffic, and Staying Put,” Molecular Cell 49, no. 5 (2013): 808–824.

[119] R. Cao, L. Wang, H. Wang, et al., “Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing,” Science 298, no. 5595 (2002): 1039–1043.

[120] M. A. Dawson and T. Kouzarides, “Cancer Epigenetics: From Mechanism to Therapy,” Cell 150, no. 1 (2012): 12–27.

[121] J. E. Bolden, M. J. Peart, and R. W. Johnstone, “Anticancer Activities of Histone Deacetylase Inhibitors,” Nature Reviews Drug Discovery 5, no. 9 (2006): 769–784.

[122] M. T. McCabe, H. M. Ott, G. Ganji, et al., “EZH2 Inhibition as a Therapeutic Strategy for Lymphoma With EZH2-activating Mutations,” Nature 492, no. 7427 (2012): 108–112.

[123] D. Zhang, Z. Tang, H. Huang, et al., “Metabolic Regulation of Gene Expression by Histone Lactylation,” Nature 574, no. 7779 (2019): 575–580.

[124] H. Rho and N. Hay, “Protein Lactylation in Cancer: Mechanisms and Potential Therapeutic Implications,” Experimental & Molecular Medicine 57, no. 3 (2025): 545–553.

[125] J. Yu, P. Chai, M. Xie, et al., “Histone Lactylation Drives Oncogenesis by Facilitating m(6)A Reader Protein YTHDF2 Expression in Ocular Melanoma,” Genome Biology 22, no. 1 (2021): 85.

[126] X. Li, Y. Yang, B. Zhang, et al., “Lactate Metabolism in Human Health and Disease,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 305.

[127] S. Nong, X. Han, Y. Xiang, et al., “Metabolic Reprogramming in Cancer: Mechanisms and Therapeutics,” MedComm 4, no. 2 (2023): e218.

[128] K. Yang, M. Fan, X. Wang, et al., “Lactate Promotes Macrophage HMGB1 Lactylation, Acetylation, and Exosomal Release in Polymicrobial Sepsis,” Cell Death & Differentiation 29, no. 1 (2022): 133–146.

[129] L. T. Izzo and K. E. Wellen, “Histone Lactylation Links Metabolism and Gene Regulation,” Nature 574, no. 7779 (2019): 492–493.

[130] D. Rossetto, N. Avvakumov, and J. Côté, “Histone Phosphorylation: A Chromatin Modification Involved in Diverse Nuclear Events,” Epigenetics 7, no. 10 (2012): 1098–1108.

[131] H. Goto, H. Kosako, Y. Tomono, et al., “Identification of a Novel Phosphorylation Site on Histone H3 Coupled With Mitotic Chromosome Condensation,” Journal of Biological Chemistry 274, no. 36 (1999): 25543–25549.

[132] A. Armache, S. Yang, A. Martínez de Paz, et al., “Histone H3.3 Phosphorylation Amplifies Stimulation-Induced Transcription,” Nature 583, no. 7818 (2020): 852–857.

[133] O. Gavet and J. Pines, “Activation of Cyclin B1-Cdk1 Synchronizes Events in the Nucleus and the Cytoplasm at Mitosis,” Journal of Cell Biology 189, no. 2 (2010): 247–259.

[134] J. Dai, S. Sultan, S. S. Taylor, and J. M. Higgins, “The Kinase Haspin Is Required for Mitotic Histone H3 Thr 3 Phosphorylation and Normal Metaphase Chromosome Alignment,” Genes & Development 19, no. 4 (2005): 472–488.

[135] E. P. Rogakou, D. R. Pilch, A. H. Orr, V. S. Ivanova, and W. M. Bonner, “DNA Double-Stranded Breaks Induce Histone H2AX Phosphorylation on Serine 139,” Journal of Biological Chemistry 273, no. 10 (1998): 5858–5868.

[136] W. M. Bonner, C. E. Redon, J. S. Dickey, et al., “γH2AX and Cancer,” Nature Reviews Cancer 8, no. 12 (2008): 957–967.

[137] A. Sawicka and C. Seiser, “Histone H3 Phosphorylation—A Versatile Chromatin Modification for Different Occasions,” Biochimie 94, no. 11 (2012): 2193–2201.

[138] M. Esteller, “Non-Coding RNAs in Human Disease,” Nature Reviews Genetics 12, no. 12 (2011): 861–874.

[139] I. Ulitsky and D. P. Bartel, “lincRNAs: Genomics, Evolution, and Mechanisms,” Cell 154, no. 1 (2013): 26–46.

[140] D. P. Bartel, “MicroRNAs,” Cell 116, no. 2 (2004): 281–297.

[141] V. Ambros, “MicroRNAs,” Cell 107, no. 7 (2001): 823–826.

[142] T. R. Leonardo, H. L. Schultheisz, J. F. Loring, and L. C. Laurent, “The Functions of microRNAs in Pluripotency and Reprogramming,” Nature Cell Biology 14, no. 11 (2012): 1114–1121.

[143] G. A. Calin and C. M. Croce, “MicroRNA Signatures in Human Cancers,” Nature Reviews Cancer 6, no. 11 (2006): 857–866.

[144] Z. Ali Syeda, S. S. S. Langden, C. Munkhzul, M. Lee, and S. J. Song, “Regulatory Mechanism of MicroRNA Expression in Cancer,” International Journal of Molecular Sciences 21, no. 5 (2020): 1723.

[145] S. M. Johnson, H. Grosshans, J. Shingara, et al., “RAS Is Regulated by the let-7 microRNA Family,” Cell 120, no. 5 (2005): 635–647.

[146] F. Meng, R. Henson, H. Wehbe–Janek, K. Ghoshal, S. T. Jacob, and T. Patel, “MicroRNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer,” Gastroenterology 133, no. 2 (2007): 647–658.

[147] J. L. Rinn and H. Y. Chang, “Genome Regulation by Long Noncoding RNAs,” Annual Review of Biochemistry 81 (2012): 145–166.

[148] R. Galupa and E. Heard, “X-Chromosome Inactivation: New Insights Into cis and Trans Regulation,” Current Opinion in Genetics & Development 31 (2015): 57–66.

[149] I. Dror, T. Chitiashvili, S. Y. X. Tan, et al., “XIST Directly Regulates X-Linked and Autosomal Genes in Naive Human Pluripotent Cells,” Cell 187, no. 1 (2024): 110–129.e31.

[150] J. R. Prensner and A. M. Chinnaiyan, “The Emergence of LncRNAs in Cancer Biology,” Cancer Discovery 1, no. 5 (2011): 391–407.

[151] R. A. Gupta, N. Shah, K. C. Wang, et al., “Long Non-Coding RNA Hotair Reprograms Chromatin State to Promote Cancer Metastasis,” Nature 464, no. 7291 (2010): 1071–1076.

[152] V. Tripathi, J. D. Ellis, Z. Shen, et al., “The Nuclear-Retained Noncoding RNA MALAT1 Regulates Alternative Splicing by Modulating SR Splicing Factor Phosphorylation,” Molecular Cell 39, no. 6 (2010): 925–938.

[153] G. Arun, D. Aggarwal, and D. L. Spector, “MALAT1 Long Non-Coding RNA: Functional Implications,” Non-coding RNA 6, no. 2 (2020): 22.

[154] A. J. Bannister and T. Kouzarides, “Regulation of Chromatin by Histone Modifications,” Cell Research 21, no. 3 (2011): 381–395.

[155] C. R. Clapier and B. R. Cairns, “The Biology of Chromatin Remodeling Complexes,” Annual Review of Biochemistry 78 (2009): 273–304.

[156] L. Ho and G. R. Crabtree, “Chromatin Remodelling During Development,” Nature 463, no. 7280 (2010): 474–484.

[157] M. C. Church and J. L. Workman, “The SWI/SNF Chromatin Remodeling Complex: A Critical Regulator of Metabolism,” Biochemical Society Transactions 52, no. 3 (2024): 1327–1337.

[158] M. D. Allen, S. M. V. Freund, M. Bycroft, and G. Zinzalla, “SWI/SNF Subunit BAF155 N-Terminus Structure Informs the Impact of Cancer-Associated Mutations and Reveals a Potential Drug Binding Site,” Communications Biology 4, no. 1 (2021): 528.

[159] K. C. Wiegand, S. P. Shah, O. M. Al-Agha, et al., “ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas,” New England Journal of Medicine 363, no. 16 (2010): 1532–1543.

[160] B. G. Wilson and C. W. M. Roberts, “SWI/SNF Nucleosome Remodellers and Cancer,” Nature Reviews Cancer 11, no. 7 (2011): 481–492.

[161] Y. Li, H. Gong, P. Wang, et al., “The Emerging Role of ISWI Chromatin Remodeling Complexes in Cancer,” Journal of Experimental & Clinical Cancer Research 40, no. 1 (2021): 346.

[162] Y. Tian, L. Xu, X. Li, H. Li, and M. Zhao, “SMARCA4: Current Status and Future Perspectives in Non-Small-Cell Lung Cancer,” Cancer Letters 554 (2023): 216022.

[163] A. J. Ruthenburg, C. D. Allis, and J. Wysocka, “Methylation of Lysine 4 on Histone H3: Intricacy of Writing and Reading a Single Epigenetic Mark,” Molecular Cell 25, no. 1 (2007): 15–30.

[164] A. P. Feinberg and B. Tycko, “The History of Cancer Epigenetics,” Nature Reviews Cancer 4, no. 2 (2004): 143–153.

[165] P. A. Jones and S. B. Baylin, “The Epigenomics of Cancer,” Cell 128, no. 4 (2007): 683–692.

[166] R. Nusse and H. Clevers, “Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities,” Cell 169, no. 6 (2017): 985–999.

[167] T. Zhan, N. Rindtorff, and M. Boutros, “Wnt Signaling in Cancer,” Oncogene 36, no. 11 (2017): 1461–1473.

[168] H. Liu, D. Zhou, Y. Ou, et al., “Multiple Signaling Pathways in the Frontiers of Lung Cancer Progression,” Frontiers in Immunology 16 (2025): 1593793.

[169] C. Y. Logan and R. Nusse, “The Wnt Signaling Pathway in Development and Disease,” Annual Review of Cell and Developmental Biology 20 (2004): 781–810.

[170] B. T. MacDonald, K. Tamai, and X. He, “Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases,” Developmental Cell 17, no. 1 (2009): 9–26.

[171] T. C. He, A. B. Sparks, C. Rago, et al., “Identification of c-MYC as a Target of the APC Pathway,” Science 281, no. 5382 (1998): 1509–1512.

[172] S. Chatterjee and P. C. Sil, “Targeting the Crosstalks of Wnt Pathway With Hedgehog and Notch for Cancer Therapy,” Pharmacological Research 142 (2019): 251–261.

[173] P. J. Morin, A. B. Sparks, V. Korinek, et al., “Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC,” Science 275, no. 5307 (1997): 1787–1790.

[174] J. N. Anastas and R. T. Moon, “WNT Signalling Pathways as Therapeutic Targets in Cancer,” Nature Reviews Cancer 13, no. 1 (2013): 11–26.

[175] A. P. South, R. J. Cho, and J. C. Aster, “The Double-Edged Sword of Notch Signaling in Cancer,” Seminars in Cell & Developmental Biology 23, no. 4 (2012): 458–464.

[176] R. Kopan and M. X. G. Ilagan, “The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism,” Cell 137, no. 2 (2009): 216–233.

[177] S. J. Bray, “Notch Signalling in Context,” Nature Reviews Molecular Cell Biology 17, no. 11 (2016): 722–735.

[178] A. P. Weng, A. A. Ferrando, W. Lee, et al., “Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia,” Science 306, no. 5694 (2004): 269–271.

[179] M. Pelullo, S. Zema, F. Nardozza, S. Checquolo, I. Screpanti, and D. Bellavia, “Wnt, Notch, and TGF-β Pathways Impinge on Hedgehog Signaling Complexity: An Open Window on Cancer,” Frontiers in Genetics 10 (2019): 711.

[180] J. A. Clara, C. Monge, Y. Yang, and N. Takebe, “Targeting Signalling Pathways and the Immune Microenvironment of Cancer Stem Cells—A Clinical Update,” Nature Reviews Clinical Oncology 17, no. 4 (2020): 204–232.

[181] A. Klinakis, C. Lobry, O. Abdel-Wahab, et al., “A Novel Tumour-Suppressor Function for the Notch Pathway in Myeloid Leukaemia,” Nature 473, no. 7346 (2011): 230–233.

[182] X. Zeng and D. Ju, “Hedgehog Signaling Pathway and Autophagy in Cancer,” International Journal of Molecular Sciences 19, no. 8 (2018): 2279.

[183] P. W. Ingham and A. P. McMahon, “Hedgehog Signaling in Animal Development: Paradigms and Principles,” Genes & Development 15, no. 23 (2001): 3059–3087.

[184] J. Taipale and P. A. Beachy, “The Hedgehog and Wnt Signalling Pathways in Cancer,” Nature 411, no. 6835 (2001): 349–354.

[185] M. Varjosalo and J. Taipale, “Hedgehog: Functions and Mechanisms,” Genes & Development 22, no. 18 (2008): 2454–2472.

[186] X. Wei, W. Liu, J. Q. Wang, and Z. Tang, “‘Hedgehog Pathway’: A Potential Target of Itraconazole in the Treatment of Cancer,” Journal of Cancer Research and Clinical Oncology 146, no. 2 (2020): 297–304.

[187] J. Jiang, “Hedgehog Signaling Mechanism and Role in Cancer,” Seminars in Cancer Biology 85 (2022): 107–122.

[188] H. J. Sharpe, G. Pau, G. J. Dijkgraaf, et al., “Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma,” Cancer Cell 27, no. 3 (2015): 327–341.

[189] J. Massagué, “TGFβ in Cancer,” Cell 134, no. 2 (2008): 215–230.

[190] Y. Shi and J. Massagué, “Mechanisms of TGF-β Signaling From Cell Membrane to the Nucleus,” Cell 113, no. 6 (2003): 685–700.

[191] C. H. Heldin and A. Moustakas, “Role of Smads in TGFβ Signaling,” Cell and Tissue Research 347, no. 1 (2012): 21–36.

[192] Y. E. Zhang, “Non-Smad Pathways in TGF-β Signaling,” Cell Research 19, no. 1 (2009): 128–139.

[193] J. Seoane, H. V. Le, L. Shen, S. A. Anderson, and J. Massagué, “Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation,” Cell 117, no. 2 (2004): 211–223.

[194] R. Derynck, S. J. Turley, and R. J. Akhurst, “TGFβ Biology in Cancer Progression and Immunotherapy,” Nature Reviews Clinical Oncology 18, no. 1 (2021): 9–34.

[195] H. Ikushima and K. Miyazono, “TGFβ Signalling: A Complex Web in Cancer Progression,” Nature Reviews Cancer 10, no. 6 (2010): 415–424.

[196] D. Hanahan, “Hallmarks of Cancer: New Dimensions,” Cancer Discovery 12, no. 1 (2022): 31–46.

[197] A. Hu, L. Sun, H. Lin, Y. Liao, H. Yang, and Y. Mao, “Harnessing Innate Immune Pathways for Therapeutic Advancement in Cancer,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 68.

[198] M. Oginuma, Y. Harima, O. A. Tarazona, et al., “Intracellular pH Controls Wnt Downstream of Glycolysis in Amniote Embryos,” Nature 584, no. 7819 (2020): 98–101.

[199] A. Sharma, J. J. W. Seow, C. A. Dutertre, et al., “Onco-Fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma,” Cell 183, no. 2 (2020): 377–394.e21.

[200] K. Liu, J. J. Cui, Y. Zhan, et al., “Reprogramming the Tumor Microenvironment by Genome Editing for Precision Cancer Therapy,” Molecular Cancer 21, no. 1 (2022): 98.

[201] D. F. Quail and J. A. Joyce, “Microenvironmental Regulation of Tumor Progression and Metastasis,” Nature Medicine 19, no. 11 (2013): 1423–1437.

[202] R. A. Franklin, W. Liao, A. Sarkar, et al., “The Cellular and Molecular Origin of Tumor-Associated Macrophages,” Science 344, no. 6186 (2014): 921–925.

[203] B. Z. Qian and J. W. Pollard, “Macrophage Diversity Enhances Tumor Progression and Metastasis,” Cell 141, no. 1 (2010): 39–51.

[204] A. Sica and A. Mantovani, “Macrophage Plasticity and Polarization: In Vivo Veritas,” Journal of Clinical Investigation 122, no. 3 (2012): 787–795.

[205] Z. G. Fridlender, J. Sun, S. Kim, et al., “Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: ‘N1’ versus ‘N2’ TAN,” Cancer Cell 16, no. 3 (2009): 183–194.

[206] T. F. Gajewski, H. Schreiber, and Y. X. Fu, “Innate and Adaptive Immune Cells in the Tumor Microenvironment,” Nature Immunology 14, no. 10 (2013): 1014–1022.

[207] Y. Zhu, B. L. Knolhoff, M. A. Meyer, et al., “CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-Cell Checkpoint Immunotherapy in Pancreatic Cancer Models,” Cancer Research 74, no. 18 (2014): 5057–5069.

[208] J. J. O'Shea and W. E. Paul, “Mechanisms Underlying Lineage Commitment and Plasticity of Helper CD4+ T Cells,” Science 327, no. 5969 (2010): 1098–1102.

[209] E. Vivier, E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini, “Functions of Natural Killer Cells,” Nature Immunology 9, no. 5 (2008): 503–510.

[210] J. S. Nielsen, R. A. Sahota, K. Milne, et al., “CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27- Memory Phenotype and Together With CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer,” Clinical Cancer Research 18, no. 12 (2012): 3281–3292.

[211] S. Varmazyari, H. Borhani, Z. Moradipour, H. Ziaei, and N. Rezaei, “Characterizing the Head and Neck Cancer Microenvironment: Implications for Immunotherapy and Prognosis,” Advances in Experimental Medicine and Biology 1492 (2026): 363–397.

[212] S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity, Inflammation, and Cancer,” Cell 140, no. 6 (2010): 883–899.

[213] P. B. Gupta, C. M. Fillmore, G. Jiang, et al., “Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells,” Cell 146, no. 4 (2011): 633–644.

[214] D. S. Chen and I. Mellman, “Oncology Meets Immunology: The Cancer-Immunity Cycle,” Immunity 39, no. 1 (2013): 1–10.

[215] M. Binnewies, E. W. Roberts, K. Kersten, et al., “Understanding the Tumor Immune Microenvironment (TIME) for Effective Therapy,” Nature Medicine 24, no. 5 (2018): 541–550.

[216] L. Chen and X. Han, “Anti-PD-1/PD-L1 Therapy of Human Cancer: Past, Present, and Future,” Journal of Clinical Investigation 125, no. 9 (2015): 3384–3391.

[217] F. Garrido, N. Aptsiauri, E. M. Doorduijn, A. M. Garcia Lora, and T. van Hall, “The Urgent Need to Recover MHC Class I in Cancers for Effective Immunotherapy,” Current Opinion in Immunology 39 (2016): 44–51.

[218] P. Sharma and J. P. Allison, “The Future of Immune Checkpoint Therapy,” Science 348, no. 6230 (2015): 56–61.

[219] M. M. Gubin, X. Zhang, H. Schuster, et al., “Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens,” Nature 515, no. 7528 (2014): 577–581.

[220] M. S. Rooney, S. A. Shukla, C. J. Wu, G. Getz, and N. Hacohen, “Molecular and Genetic Properties of Tumors Associated With Local Immune Cytolytic Activity,” Cell 160, no. 1–2 (2015): 48–61.

[221] P. Paul, N. Rouas-Freiss, I. Khalil-Daher, et al., “HLA-G Expression in Melanoma: A Way for Tumor Cells to Escape From Immunosurveillance,” Proceedings of the National Academy of Sciences 95, no. 8 (1998): 4510–4515.

[222] P. Sharma and J. P. Allison, “Dissecting the Mechanisms of Immune Checkpoint Therapy,” Nature Reviews Immunology 20, no. 2 (2020): 75–76.

[223] S. C. Casey, L. Tong, Y. Li, et al., “MYC Regulates the Antitumor Immune Response Through CD47 and PD-L1,” Science 352, no. 6282 (2016): 227–231.

[224] A. C. Anderson, N. Joller, and V. K. Kuchroo, “Lag-3, Tim-3, and TIGIT: Co-Inhibitory Receptors With Specialized Functions in Immune Regulation,” Immunity 44, no. 5 (2016): 989–1004.

[225] E. J. Wherry and M. Kurachi, “Molecular and Cellular Insights Into T Cell Exhaustion,” Nature Reviews Immunology 15, no. 8 (2015): 486–499.

[226] D. I. Gabrilovich and S. Nagaraj, “Myeloid-Derived Suppressor Cells as Regulators of the Immune System,” Nature Reviews Immunology 9, no. 3 (2009): 162–174.

[227] L. Zhou, M. M. W. Chong, and D. R. Littman, “Plasticity of CD4+ T Cell Lineage Differentiation,” Immunity 30, no. 5 (2009): 646–655.

[228] K. Wing, Y. Onishi, P. Prieto-Martin, et al., “CTLA-4 Control Over Foxp3+ Regulatory T Cell Function,” Science 322, no. 5899 (2008): 271–275.

[229] S. Sakaguchi, T. Yamaguchi, T. Nomura, and M. Ono, “Regulatory T Cells and Immune Tolerance,” Cell 133, no. 5 (2008): 775–787.

[230] M. Kraman, P. J. Bambrough, J. N. Arnold, et al., “Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α,” Science 330, no. 6005 (2010): 827–830.

[231] C. H. Chang, J. Qiu, D. O'Sullivan, et al., “Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression,” Cell 162, no. 6 (2015): 1229–1241.

[232] L. Salamonsen, N. Hannan, and E. Dimitriadis, “Cytokines and Chemokines During Human Embryo Implantation: Roles in Implantation and Early Placentation,” Seminars in Reproductive Medicine 25, no. 6 (2007): 437–444.

[233] M. Dahlström, G. Nordvall, E. Sundström, et al., “Identification of Amino Acid Residues of Nerve Growth Factor Important for Neurite Outgrowth in Human Dorsal Root Ganglion Neurons,” European Journal of Neuroscience 50, no. 9 (2019): 3487–3501.

[234] B. N. Nelson and J. E. Friedman, “Developmental Programming of the Fetal Immune System by Maternal Western-Style Diet: Mechanisms and Implications for Disease Pathways in the Offspring,” International Journal of Molecular Sciences 25, no. 11 (2024): 5951.

[235] Y. Yarden and M. X. Sliwkowski, “Untangling the ErbB Signalling Network,” Nature Reviews Molecular Cell Biology 2, no. 2 (2001): 127–137.

[236] C. Garlanda, I. Di Ceglie, and S. Jaillon, “IL-1 Family Cytokines in Inflammation and Immunity,” Cellular & Molecular Immunology 22, no. 11 (2025): 1345–1362.

[237] F. Balkwill and A. Mantovani, “Inflammation and Cancer: Back to Virchow?,” Lancet 357, no. 9255 (2001): 539–545.

[238] P. Friedl and K. Wolf, “Tumour-Cell Invasion and Migration: Diversity and Escape Mechanisms,” Nature Reviews Cancer 3, no. 5 (2003): 362–374.

[239] W. L. Liao, Y. Y. Wu, Y. F. Liu, et al., “rFIP-GMI Suppresses IGF-1-Induced Invasion and Migration in Breast Cancer Cells via PI3K/Akt/β-Catenin Inhibition,” Drug Development Research 86, no. 8 (2025): e70202.

[240] D. H. Kim, T. Xing, Z. Yang, R. Dudek, Q. Lu, and Y. H. Chen, “Epithelial Mesenchymal Transition in Embryonic Development, Tissue Repair and Cancer: A Comprehensive Overview,” Journal of Clinical Medicine 7, no. 1 (2018): 1.

[241] I. Pastushenko and C. Blanpain, “EMT Transition States During Tumor Progression and Metastasis,” Trends in Cell Biology 29, no. 3 (2019): 212–226.

[242] A. Dongre and R. A. Weinberg, “New Insights Into the Mechanisms of Epithelial-Mesenchymal Transition and Implications for Cancer,” Nature Reviews Molecular Cell Biology 20, no. 2 (2019): 69–84.

[243] T. Iwasawa, R. Hatano, S. Takeda, et al., “Anti-CD26 Antibody Suppresses Epithelial-Mesenchymal Transition in Colorectal Cancer Stem Cells,” International Journal of Molecular Sciences 26, no. 15 (2025): 7620.

[244] Z. Zheng, L. Zhao, S. Zhao, Z. Wu, and N. Wu, “A Rare Germline Mutation Reverses the Suppressive Effect of GPC5 Thereby Promoting Lung Adenocarcinoma Development and Tumorigenesis,” Frontiers in Genetics 16 (2025): 1582504.

[245] P. Xia, “The Significance of Epithelial-Mesenchymal Transition (EMT) in the Initiation, Plasticity, and Treatment of Glioblastoma,” Genes & Diseases 13, no. 1 (2026): 101711.

[246] L. Du, X. Chen, Y. Cao, et al., “Overexpression of PIK3CA in Murine Head and Neck Epithelium Drives Tumor Invasion and Metastasis Through PDK1 and Enhanced TGFβ Signaling,” Oncogene 35, no. 35 (2016): 4641–4652.

[247] E. Sánchez-Tilló, O. de Barrios, L. Siles, M. Cuatrecasas, A. Castells, and A. Postigo, “β-Catenin/TCF4 Complex Induces the Epithelial-to-Mesenchymal Transition (EMT)-Activator ZEB1 to Regulate Tumor Invasiveness,” Proceedings of the National Academy of Sciences 108, no. 48 (2011): 19204–19209.

[248] H. Clevers and R. Nusse, “Wnt/β-Catenin Signaling and Disease,” Cell 149, no. 6 (2012): 1192–1205.

[249] L. Zhang, X. Zhang, X. Deng, et al., “Cytokines as Drivers: Unraveling the Mechanisms of Epithelial-Mesenchymal Transition in COVID-19 Lung Fibrosis,” Biochemical and Biophysical Research Communications 686 (2023): 149118.

[250] R. Thapa, S. Gupta, G. Gupta, et al., “Epithelial-Mesenchymal Transition to Mitigate Age-Related Progression in Lung Cancer,” Ageing Research Reviews 102 (2024): 102576.

[251] Y. Huang, W. Hong, and X. Wei, “The Molecular Mechanisms and Therapeutic Strategies of EMT in Tumor Progression and Metastasis,” Journal of Hematology & Oncology 15, no. 1 (2022): 129.

[252] G. Shan, W. Wang, X. Li, et al., “Epigenetic-Targeted Biomimetic Nanomedicine Modulates Epithelial Mesenchymal Transition to Enhance Chemosensitivity in Heterogeneous Tumors,” Biomaterials 324 (2026): 123529.

[253] J. Yang and R. A. Weinberg, “Epithelial-Mesenchymal Transition: At the Crossroads of Development and Tumor Metastasis,” Developmental Cell 14, no. 6 (2008): 818–829.

[254] R. A. Sample, M. F. Nogueira, R. D. Mitra, and S. V. Puram, “Epigenetic Regulation of Hybrid Epithelial-Mesenchymal Cell States in Cancer,” Oncogene 42, no. 29 (2023): 2237–2248.

[255] S. Tanabe, S. Quader, H. Cabral, and R. Ono, “Interplay of EMT and CSC in Cancer and the Potential Therapeutic Strategies,” Frontiers in Pharmacology 11 (2020): 904.

[256] S. A. Mani, W. Guo, M. J. Liao, et al., “The Epithelial-Mesenchymal Transition Generates Cells With Properties of Stem Cells,” Cell 133, no. 4 (2008): 704–715.

[257] C. Galassi, G. Manic, M. Esteller, L. Galluzzi, and I. Vitale, “Epigenetic Regulation of Cancer Stemness,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 243.

[258] Y. Hao, D. Baker, and P. Ten Dijke, “TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis,” International Journal of Molecular Sciences 20, no. 11 (2019): 2767.

[259] D. M. Gonzalez and D. Medici, “Signaling Mechanisms of the Epithelial-Mesenchymal Transition,” Science Signaling 7, no. 344 (2014): re8.

[260] R. O. Hynes, “Integrins,” Cell 110, no. 6 (2002): 673–687.

[261] S. To, T. Chavula, M. Pedroza, J. Smith, and S. K. Agarwal, “Cadherin-11 Regulates Macrophage Development and Function,” Frontiers in Immunology 13 (2022): 795337.

[262] H. Acloque, M. S. Adams, K. Fishwick, M. Bronner-Fraser, and M. A. Nieto, “Epithelial-Mesenchymal Transitions: The Importance of Changing Cell State in Development and Disease,” Journal of Clinical Investigation 119, no. 6 (2009): 1438–1449.

[263] L. Shapiro, A. M. Fannon, P. D. Kwong, et al., “Structural Basis of Cell-Cell Adhesion by Cadherins,” Nature 374, no. 6520 (1995): 327–337.

[264] A. K. Perl, P. Wilgenbus, U. Dahl, H. Semb, and G. Christofori, “A Causal Role for E-Cadherin in the Transition From Adenoma to Carcinoma,” Nature 392, no. 6672 (1998): 190–193.

[265] L. Xie, J. Wang, L. Song, T. Jiang, and F. Yan, “Cell-Cycle Dependent Nuclear Gene Delivery Enhances the Effects of E-Cadherin Against Tumor Invasion and Metastasis,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 182.

[266] L. D. M. Derycke and M. E. Bracke, “N-Cadherin in the Spotlight of Cell-Cell Adhesion, Differentiation, Embryogenesis, Invasion and Signalling,” International Journal of Developmental Biology 48, no. 5–6 (2004): 463–476.

[267] X. Liao, Y. Xu, H. Zhou, Q. Yi, S. Dong, and B. Tan, “S100B Drives Glioblastoma Invasion and Migration Through TGF‑β2‑Mediated Epithelial‑Mesenchymal Transition,” Oncology Reports 55, no. 1 (2026): 20.

[268] L. Liu, Q. Sun, F. Davis, J. Mao, H. Zhao, and D. Ma, “Epithelial-Mesenchymal Transition in Organ Fibrosis Development: Current Understanding and Treatment Strategies,” Burns & Trauma 10 (2022): 11.

[269] T. Celià-Terrassa and Y. Kang, “Distinctive Properties of Metastasis-Initiating Cells,” Genes & Development 30, no. 8 (2016): 892–908.

[270] L. Fattet, H. Y. Jung, M. W. Matsumoto, et al., “Matrix Rigidity Controls Epithelial-Mesenchymal Plasticity and Tumor Metastasis via a Mechanoresponsive EPHA2/LYN Complex,” Developmental Cell 54, no. 3 (2020): 302–316.e7.

[271] H. Hamidi and J. Ivaska, “Every Step of the Way: Integrins in Cancer Progression and Metastasis,” Nature Reviews Cancer 18, no. 9 (2018): 533–548.

[272] Z. Sun, S. S. Guo, and R. Fässler, “Integrin-Mediated Mechanotransduction,” Journal of Cell Biology 215, no. 4 (2016): 445–456.

[273] R. O. Hynes, “The Extracellular Matrix: Not Just Pretty Fibrils,” Science 326, no. 5957 (2009): 1216–1219.

[274] P. Lu, K. Takai, V. M. Weaver, and Z. Werb, “Extracellular Matrix Degradation and Remodeling in Development and Disease,” Cold Spring Harbor Perspectives in Biology 3, no. 12 (2011): a005058.

[275] J. A. Eble and S. Niland, “The Extracellular Matrix in Tumor Progression and Metastasis,” Clinical & Experimental Metastasis 36, no. 3 (2019): 171–198.

[276] R. Kalluri and M. Zeisberg, “Fibroblasts in Cancer,” Nature Reviews Cancer 6, no. 5 (2006): 392–401.

[277] M. W. Pickup, J. K. Mouw, and V. M. Weaver, “The Extracellular Matrix Modulates the Hallmarks of Cancer,” EMBO Reports 15, no. 12 (2014): 1243–1253.

[278] P. P. Provenzano, D. R. Inman, K. W. Eliceiri, et al., “Collagen Density Promotes Mammary Tumor Initiation and Progression,” BMC Medicine 6 (2008): 11.

[279] K. R. Levental, H. Yu, L. Kass, et al., “Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling,” Cell 139, no. 5 (2009): 891–906.

[280] C. Bonnans, J. Chou, and Z. Werb, “Remodelling the Extracellular Matrix in Development and Disease,” Nature Reviews Molecular Cell Biology 15, no. 12 (2014): 786–801.

[281] C. Gialeli, A. D. Theocharis, and N. K. Karamanos, “Roles of Matrix Metalloproteinases in Cancer Progression and Their Pharmacological Targeting,” FEBS Journal 278, no. 1 (2011): 16–27.

[282] S. D. Mason and J. A. Joyce, “Proteolytic Networks in Cancer,” Trends in Cell Biology 21, no. 4 (2011): 228–237.

[283] V. Arpino, M. Brock, and S. E. Gill, “The Role of TIMPs in Regulation of Extracellular Matrix Proteolysis,” Matrix Biology 44–46 (2015): 247–254.

[284] C. López-Otín and L. M. Matrisian, “Emerging Roles of Proteases in Tumour Suppression,” Nature Reviews Cancer 7, no. 10 (2007): 800–808.

[285] A. Becchetti, C. Duranti, and A. Arcangeli, “Dynamics and Physiological Meaning of Complexes Between Ion Channels and Integrin Receptors: The Case of Kv11.1,” American Journal of Physiology-Cell Physiology 322, no. 6 (2022): C1138–C1150.

[286] V. T. Hoang, M. D. Matossian, D. A. Ucar, et al., “ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer,” Frontiers in Oncology 10 (2020): 1164.

[287] E. Sahai, I. Astsaturov, E. Cukierman, et al., “A Framework for Advancing Our Understanding of Cancer-Associated Fibroblasts,” Nature Reviews Cancer 20, no. 3 (2020): 174–186.

[288] J. Folkman, “Angiogenesis: An Organizing Principle for Drug Discovery?,” Nature Reviews Drug Discovery 6, no. 4 (2007): 273–286.

[289] P. Carmeliet and R. K. Jain, “Molecular Mechanisms and Clinical Applications of Angiogenesis,” Nature 473, no. 7347 (2011): 298–307.

[290] R. K. Jain, “Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia,” Cancer Cell 26, no. 5 (2014): 605–622.

[291] N. Ferrara, K. J. Hillan, H. P. Gerber, and W. Novotny, “Discovery and Development of Bevacizumab, an Anti-VEGF Antibody for Treating Cancer,” Nature Reviews Drug Discovery 3, no. 5 (2004): 391–400.

[292] R. K. Jain, “Normalizing Tumor Vasculature With Anti-Angiogenic Therapy: A New Paradigm for Combination Therapy,” Nature Medicine 7, no. 9 (2001): 987–989.

[293] H. Imafuji, Y. Matsuo, G. Ueda, et al., “Acquisition of Gemcitabine Resistance Enhances Angiogenesis via Upregulation of IL‑8 Production in Pancreatic Cancer,” Oncology Reports 41, no. 6 (2019): 3508–3516.

[294] R. K. Jain, “Delivery of Molecular and Cellular Medicine to Solid Tumors,” supplement, Advanced Drug Delivery Reviews 64, no. Suppl (2012): 353–365.

[295] S. Goel, D. G. Duda, L. Xu, et al., “Normalization of the Vasculature for Treatment of Cancer and Other Diseases,” Physiological Reviews 91, no. 3 (2011): 1071–1121.

[296] P. Carmeliet and R. K. Jain, “Principles and Mechanisms of Vessel Normalization for Cancer and Other Angiogenic Diseases,” Nature Reviews Drug Discovery 10, no. 6 (2011): 417–427.

[297] H. Hurwitz, L. Fehrenbacher, W. Novotny, et al., “Bevacizumab Plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer,” New England Journal of Medicine 350, no. 23 (2004): 2335–2342.

[298] J. M. L. Ebos, C. R. Lee, W. Cruz-Munoz, G. A. Bjarnason, J. G. Christensen, and R. S. Kerbel, “Accelerated Metastasis After Short-Term Treatment With a Potent Inhibitor of Tumor Angiogenesis,” Cancer Cell 15, no. 3 (2009): 232–239.

[299] G. Bergers and D. Hanahan, “Modes of Resistance to Anti-Angiogenic Therapy,” Nature Reviews Cancer 8, no. 8 (2008): 592–603.

[300] S. P. Jackson and J. Bartek, “The DNA-Damage Response in Human Biology and Disease,” Nature 461, no. 7267 (2009): 1071–1078.

[301] A. Ciccia and S. J. Elledge, “The DNA Damage Response: Making It Safe to Play With Knives,” Molecular Cell 40, no. 2 (2010): 179–204.

[302] T. Lindahl and R. D. Wood, “Quality Control by DNA Repair,” Science 286, no. 5446 (1999): 1897–1905.

[303] H. E. Krokan and M. Bjoras, “Base Excision Repair,” Cold Spring Harbor Perspectives in Biology 5, no. 4 (2013): a012583.

[304] J. A. Marteijn, S. Bekker-Jensen, N. Mailand, et al., “Nucleotide Excision Repair-Induced H2A Ubiquitination Is Dependent on MDC1 and RNF8 and Reveals a Universal DNA Damage Response,” Journal of Cell Biology 186, no. 6 (2009): 835–847.

[305] R. Scully, A. Panday, R. Elango, and N. A. Willis, “DNA Double-Strand Break Repair-Pathway Choice in Somatic Mammalian Cells,” Nature Reviews Molecular Cell Biology 20, no. 11 (2019): 698–714.

[306] J. H. J. Hoeijmakers, “Genome Maintenance Mechanisms for Preventing Cancer,” Nature 411, no. 6835 (2001): 366–374.

[307] C. J. Lord and A. Ashworth, “BRCAness Revisited,” Nature Reviews Cancer 16, no. 2 (2016): 110–120.

[308] M. B. Kastan and J. Bartek, “Cell-Cycle Checkpoints and Cancer,” Nature 432, no. 7015 (2004): 316–323.

[309] M. J. O'Connor, “Targeting the DNA Damage Response in Cancer,” Molecular Cell 60, no. 4 (2015): 547–560.

[310] S. Negrini, V. G. Gorgoulis, and T. D. Halazonetis, “Genomic Instability--An Evolving Hallmark of Cancer,” Nature Reviews Molecular Cell Biology 11, no. 3 (2010): 220–228.

[311] C. Lengauer, K. W. Kinzler, and B. Vogelstein, “Genetic Instabilities in Human Cancers,” Nature 396, no. 6712 (1998): 643–649.

[312] N. Vargas-Rondón, V. Villegas, and M. Rondón-Lagos, “The Role of Chromosomal Instability in Cancer and Therapeutic Responses,” Cancers 10, no. 1 (2017): 4.

[313] E. Vilar and S. B. Gruber, “Microsatellite Instability in Colorectal Cancer-The Stable Evidence,” Nature Reviews Clinical Oncology 7, no. 3 (2010): 153–162.

[314] X. Chen, A. S. Agustinus, J. Li, M. DiBona, and S. F. Bakhoum, “Chromosomal Instability as a Driver of Cancer Progression,” Nature Reviews Genetics 26, no. 1 (2025): 31–46.

[315] D. T. Le, J. N. Durham, K. N. Smith, et al., “Mismatch Repair Deficiency Predicts Response of Solid Tumors to PD-1 Blockade,” Science 357, no. 6349 (2017): 409–413.

[316] T. André, K. K. Shiu, T. W. Kim, et al., “Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer,” New England Journal of Medicine 383, no. 23 (2020): 2207–2218.

[317] P. C. Fong, D. S. Boss, T. A. Yap, et al., “Inhibition of Poly(ADP-Ribose) Polymerase in Tumors From BRCA Mutation Carriers,” New England Journal of Medicine 361, no. 2 (2009): 123–134.

[318] C. J. Lord and A. Ashworth, “PARP Inhibitors: Synthetic Lethality in the Clinic,” Science 355, no. 6330 (2017): 1152–1158.

[319] A. J. McNairn, C. H. Chuang, J. C. Bloom, M. D. Wallace, and J. C. Schimenti, “Female-Biased Embryonic Death From Inflammation Induced by Genomic Instability,” Nature 567, no. 7746 (2019): 105–108.

[320] M. Wang, S. Chen, and D. Ao, “Targeting DNA Repair Pathway in Cancer: Mechanisms and Clinical Application,” MedComm 2, no. 4 (2021): 654–691.

[321] H. T. Lynch and A. de la Chapelle, “Hereditary Colorectal Cancer,” New England Journal of Medicine 348, no. 10 (2003): 919–932.

[322] L. Y. Li, Y. D. Guan, X. S. Chen, J. M. Yang, and Y. Cheng, “DNA Repair Pathways in Cancer Therapy and Resistance,” Frontiers in Pharmacology 11 (2020): 629266.

[323] R. Wang, Y. Sun, C. Li, Y. Xue, and X. Ba, “Targeting the DNA Damage Response for Cancer Therapy,” International Journal of Molecular Sciences 24, no. 21 (2023): 15907.

[324] H. E. Bryant, N. Schultz, H. D. Thomas, et al., “Specific Killing of BRCA2-Deficient Tumours With Inhibitors of Poly(ADP-Ribose) Polymerase,” Nature 434, no. 7035 (2005): 913–917.

[325] Y. Qu, S. Qin, Z. Yang, et al., “Targeting the DNA Repair Pathway for Breast Cancer Therapy: Beyond the Molecular Subtypes,” Biomedicine & Pharmacotherapy 169 (2023): 115877.

[326] I. Hickson, Y. Zhao, C. J. Richardson, et al., “Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM,” Cancer Research 64, no. 24 (2004): 9152–9159.

[327] Y. Shiloh and Y. Ziv, “The ATM Protein Kinase: Regulating the Cellular Response to Genotoxic Stress, and More,” Nature Reviews Molecular Cell Biology 14, no. 4 (2013): 197–210.

[328] H. Li, Z. Y. Liu, N. Wu, Y. C. Chen, Q. Cheng, and J. Wang, “PARP Inhibitor Resistance: The Underlying Mechanisms and Clinical Implications,” Molecular Cancer 19, no. 1 (2020): 107.

[329] R. G. Bristow and R. P. Hill, “Hypoxia, DNA Repair and Genetic Instability,” Nature Reviews Cancer 8, no. 3 (2008): 180–192.

[330] C. Sauzay, A. Petit, A. M. Bourgeois, et al., “Alpha-Foetoprotein (AFP): A Multi-Purpose Marker in Hepatocellular Carcinoma,” Clinica Chimica Acta 463 (2016): 39–44.

[331] M. Robinson, S. F. Gilbert, J. A. Waters, et al., “Characterization of SOX2, OCT4 and NANOG in Ovarian Cancer Tumor-Initiating Cells,” Cancers 13, no. 2 (2021): 262.

[332] F. Wang, X. Li, M. Li, et al., “Ultra-Short Cell-Free DNA Fragments Enhance Cancer Early Detection in a Multi-Analyte Blood Test Combining Mutation, Protein and Fragmentomics,” Clinical Chemistry and Laboratory Medicine (CCLM) 62, no. 1 (2024): 168–177.

[333] P. P. Anglim, T. A. Alonzo, and I. A. Laird-Offringa, “DNA Methylation-Based Biomarkers for Early Detection of Non-Small Cell Lung Cancer: An Update,” Molecular Cancer 7 (2008): 81.

[334] S. Mo, H. Wang, L. Han, et al., “Fecal Multidimensional Assay for Non-Invasive Detection of Colorectal Cancer: Fecal Immunochemical Test, Stool DNA Mutation, Methylation, and Intestinal Bacteria Analysis,” Frontiers in Oncology 11 (2021): 643136.

[335] J. Rhim, W. Baek, Y. Seo, and J. H. Kim, “From Molecular Mechanisms to Therapeutics: Understanding MicroRNA-21 in Cancer,” Cells 11, no. 18 (2022): 2791.

[336] B. M. Hussen, S. H. A. Sulaiman, S. R. Abdullah, et al., “MiRNA-155: A Double-Edged Sword in Colorectal Cancer Progression and Drug Resistance Mechanisms,” International Journal of Biological Macromolecules 299 (2025): 140134.

[337] C. Bettegowda, M. Sausen, R. J. Leary, et al., “Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies,” Science Translational Medicine 6, no. 224 (2014): 224ra224.

[338] I. Capasso, C. Nero, G. Anderson, et al., “Circulating Tumor DNA in Endometrial Cancer: Clinical Significance and Implications,” International Journal of Gynecological Cancer 35, no. 4 (2025): 101656.

[339] E. De Paolis, A. Perrucci, G. Albertini Petroni, et al., “Genomics and Epigenomics Approaches for the Quantification of Circulating Tumor DNA in Liquid Biopsy: Relevance of a Multimodal Strategy,” International Journal of Molecular Sciences 26, no. 22 (2025): 10982.

[340] Q. Shi, C. Xue, Y. Zeng, et al., “Notch Signaling Pathway in Cancer: From Mechanistic Insights to Targeted Therapies,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 128.

[341] J. Liu, Q. Xiao, J. Xiao, et al., “Wnt/β-Catenin Signalling: Function, Biological Mechanisms, and Therapeutic Opportunities,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 3.

[342] E. Batlle and H. Clevers, “Cancer Stem Cells Revisited,” Nature Medicine 23, no. 10 (2017): 1124–1134.

[343] X. Zhou, Y. Han, Y. Fang, et al., “Antibody-Drug Conjugates: Current Challenges and Innovative Solutions for Precision Cancer Therapy,” Med 6, no. 10 (2025): 100849.

[344] C. Hu, X. Liu, Y. Zeng, J. Liu, and F. Wu, “DNA Methyltransferase Inhibitors Combination Therapy for the Treatment of Solid Tumor: Mechanism and Clinical Application,” Clinical Epigenetics 13, no. 1 (2021): 166.

[345] L. Ricci-Vitiani, D. G. Lombardi, E. Pilozzi, et al., “Identification and Expansion of Human Colon-Cancer-Initiating Cells,” Nature 445, no. 7123 (2007): 111–115.

[346] C. Ginestier, M. H. Hur, E. Charafe-Jauffret, et al., “ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome,” Cell Stem Cell 1, no. 5 (2007): 555–567.

[347] H. Ponta, L. Sherman, and P. A. Herrlich, “CD44: From Adhesion Molecules to Signalling Regulators,” Nature Reviews Molecular Cell Biology 4, no. 1 (2003): 33–45.

[348] B. Du, J. Qin, B. Lin, J. Zhang, D. Li, and M. Liu, “CAR-T Therapy in Solid Tumors,” Cancer Cell 43, no. 4 (2025): 665–679.

[349] P. Tarantino, R. Carmagnani Pestana, C. Corti, et al., “Antibody-Drug Conjugates: Smart Chemotherapy Delivery Across Tumor Histologies,” CA: A Cancer Journal for Clinicians 72, no. 2 (2022): 165–182.

[350] Y. Ogitani, T. Aida, K. Hagihara, et al., “DS-8201a, A Novel HER2-Targeting ADC With a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy With Differentiation From T-DM1,” Clinical Cancer Research 22, no. 20 (2016): 5097–5108.

[351] S. Modi, C. Saura, T. Yamashita, et al., “Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer,” New England Journal of Medicine 382, no. 7 (2020): 610–621.

[352] A. Bardia, I. A. Mayer, L. T. Vahdat, et al., “Sacituzumab Govitecan-Hziy in Refractory Metastatic Triple-Negative Breast Cancer,” New England Journal of Medicine 380, no. 8 (2019): 741–751.

[353] P. A. Trail, G. M. Dubowchik, and T. B. Lowinger, “Antibody Drug Conjugates for Treatment of Breast Cancer: Novel Targets and Diverse Approaches in ADC Design,” Pharmacology & Therapeutics 181 (2018): 126–142.

[354] M. Zhao, L. Li, C. H. Kiernan, et al., “Overcoming Immune Checkpoint Blockade Resistance in Solid Tumors With Intermittent ITK Inhibition,” Scientific Reports 13, no. 1 (2023): 15678.

[355] J. Yu, Y. Yan, S. Li, et al., “Progestogen-Driven B7-H4 Contributes to Onco-Fetal Immune Tolerance,” Cell 187, no. 17 (2024): 4713–4732.

[356] A. J. G. Simpson, O. L. Caballero, A. Jungbluth, Y. T. Chen, and L. J. Old, “Cancer/Testis Antigens, Gametogenesis and Cancer,” Nature Reviews Cancer 5, no. 8 (2005): 615–625.

[357] A. Chekaoui, M. Garofalo, B. Gad, et al., “Cancer Vaccines: An Update on Recent Achievements and Prospects for Cancer Therapy,” Clinical and Experimental Medicine 25, no. 1 (2024): 24.

[358] L. Gattinoni, D. J. Powell,., S. A. Rosenberg, and N. P. Restifo, “Adoptive Immunotherapy for Cancer: Building on Success,” Nature Reviews Immunology 6, no. 5 (2006): 383–393.

[359] P. A. Ott and C. J. Wu, “Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors,” Cancer Discovery 9, no. 4 (2019): 476–481.

[360] L. Yang, P. Shi, G. Zhao, et al., “Targeting Cancer Stem Cell Pathways for Cancer Therapy,” Signal Transduction and Targeted Therapy 5, no. 1 (2020): 8.

[361] E. Wickman, S. Lange, J. Wagner, et al., “IL-18R Supported CAR T Cells Targeting Oncofetal Tenascin C for the Immunotherapy of Pediatric Sarcoma and Brain Tumors,” Journal for Immunotherapy of Cancer 12, no. 11 (2024): e009743.

[362] Y. Zhai, G. Li, C. Pan, et al., “The Development and Potent Antitumor Efficacy of CD44/CD133 Dual-Targeting IL7Rα-Armored CAR-T Cells Against Glioblastoma,” Cancer Letters 614 (2025): 217541.

[363] C. Bergh and U. B. Wennerholm, “Long-Term Health of Children Conceived After Assisted Reproductive Technology,” Upsala Journal of Medical Sciences 125, no. 2 (2020): 152–157.

[364] Z. Guan, C. B. Begg, and R. Shen, “Predicting Cancer Risk From Germline Whole-Exome Sequencing Data Using a Novel Context-Based Variant Aggregation Approach,” Cancer Research Communications 3, no. 3 (2023): 483–488.

[365] A. Khalizieva, S. C. Moser, P. Bouwman, and J. Jonkers, “BRCA1 and BRCA2: From Cancer Susceptibility to Synthetic Lethality,” Genes & Development 39, no. 1/2 (2025): 86–108.

[366] G. A. D. Metcalf, “MicroRNAs: Circulating Biomarkers for the Early Detection of Imperceptible Cancers via Biosensor and Machine-Learning Advances,” Oncogene 43, no. 28 (2024): 2135–2142.

[367] C. Gyngell, T. Douglas, and J. Savulescu, “The Ethics of Germline Gene Editing,” Journal of Applied Philosophy 34, no. 4 (2017): 498–513.

[368] Y. L. Hu, Y. H. Fu, Y. Tabata, and J. Q. Gao, “Mesenchymal Stem Cells: A Promising Targeted-Delivery Vehicle in Cancer Gene Therapy,” Journal of Controlled Release 147, no. 2 (2010): 154–162.

[369] R. Langer and J. P. Vacanti, “Tissue Engineering,” Science 260, no. 5110 (1993): 920–926.

[370] R. Xu, X. Zhou, S. Wang, and C. Trinkle, “Tumor Organoid Models in Precision Medicine and Investigating Cancer-Stromal Interactions,” Pharmacology & Therapeutics 218 (2021): 107668.

[371] A. Atala, “Engineering Tissues, Organs and Cells,” Journal of Tissue Engineering and Regenerative Medicine 1, no. 2 (2007): 83–96.

[372] X. Ma, Q. Wang, G. Li, H. Li, S. Xu, and D. Pang, “Cancer Organoids: A Platform in Basic and Translational Research,” Genes & Diseases 11, no. 2 (2024): 614–632.

[373] H. Farmer, N. McCabe, C. J. Lord, et al., “Targeting the DNA Repair Defect in BRCA Mutant Cells as a Therapeutic Strategy,” Nature 434, no. 7035 (2005): 917–921.

[374] K. Moore, N. Colombo, G. Scambia, et al., “Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer,” New England Journal of Medicine 379, no. 26 (2018): 2495–2505.

[375] A. Sekulic, M. R. Migden, A. E. Oro, et al., “Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma,” New England Journal of Medicine 366, no. 23 (2012): 2171–2179.

[376] N. Basset-Seguin, A. Hauschild, J. J. Grob, et al., “Vismodegib in Patients With Advanced Basal Cell Carcinoma (STEVIE): A Pre-Planned Interim Analysis of an International, Open-Label Trial,” Lancet Oncology 16, no. 6 (2015): 729–736.

[377] J. P. Issa, “Optimizing Therapy With Methylation Inhibitors in Myelodysplastic Syndromes: Dose, Duration, and Patient Selection,” supplement, Nature Clinical Practice Oncology 2, no. S1 (2005): S24–S29.

[378] H. Dombret, J. F. Seymour, A. Butrym, et al., “International Phase 3 Study of Azacitidine vs Conventional Care Regimens in Older Patients With Newly Diagnosed AML With > 30% Blasts,” Blood 126, no. 3 (2015): 291–299.

[379] F. Morschhauser, H. Tilly, A. Chaidos, et al., “Tazemetostat for Patients With Relapsed or Refractory Follicular Lymphoma: An Open-Label, Single-Arm, Multicentre, Phase 2 Trial,” Lancet Oncology 21, no. 11 (2020): 1433–1442.

[380] T. Stuart and R. Satija, “Integrative Single-Cell Analysis,” Nature Reviews Genetics 20, no. 5 (2019): 257–272.

[381] A. Baysoy, Z. Bai, R. Satija, and R. Fan, “The Technological Landscape and Applications of Single-Cell Multi-Omics,” Nature Reviews Molecular Cell Biology 24, no. 10 (2023): 695–713.

[382] D. Chen, Z. Chen, H. Yang, et al., “Endocrine Cancer Organoids in Basic and Translational Medical Research,” Science China Life sciences 68, no. 10 (2025): 2842–2866.

[383] Y. Ding, J. D. Cravero, K. Adrian, and P. Grippo, “Modeling Pancreatic Cancer In Vivo: From Xenograft and Carcinogen-Induced Systems to Genetically Engineered Mice,” Pancreas 39, no. 3 (2010): 283–292.

[384] V. Marx, “Closing in on Cancer Heterogeneity With Organoids,” Nature Methods 21, no. 4 (2024): 551–554.

[385] U. Lampreht Tratar, S. Horvat, and M. Cemazar, “Transgenic Mouse Models in Cancer Research,” Frontiers in Oncology 8 (2018): 268.

[386] N. U. Nair, K. Cheng, L. Naddaf, et al., “Cross-Species Identification of Cancer Resistance-Associated Genes That May Mediate Human Cancer Risk,” Science Advances 8, no. 31 (2022): eabj7176.

[387] M. Islam, Y. Yang, A. J. Simmons, et al., “Temporal Recording of Mammalian Development and Precancer,” Nature 634, no. 8036 (2024): 1187–1195.

[388] T. A. F. Albuquerque, L. Drummond do Val, A. Doherty, and J. P. de Magalhães, “From Humans to Hydra: Patterns of Cancer Across the Tree of Life,” Biological Reviews 93, no. 3 (2018): 1715–1734.

[389] Y. J. Peng, X. Huang, and Q. Zhou, “Ethical and Policy Considerations for Human Embryo and Stem Cell Research in China,” Cell Stem Cell 27, no. 4 (2020): 511–514.

[390] F. R. Greten and S. I. Grivennikov, “Inflammation and Cancer: Triggers, Mechanisms, and Consequences,” Immunity 51, no. 1 (2019): 27–41.

[391] L. A. Diaz,. and A. Bardelli, “Liquid Biopsies: Genotyping Circulating Tumor DNA,” Journal of Clinical Oncology 32, no. 6 (2014): 579–586.

[392] C. Robert, J. Schachter, G. V. Long, et al., “Pembrolizumab Versus Ipilimumab in Advanced Melanoma,” New England Journal of Medicine 372, no. 26 (2015): 2521–2532.

[393] P. B. Gupta, I. Pastushenko, A. Skibinski, C. Blanpain, and C. Kuperwasser, “Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance,” Cell Stem Cell 24, no. 1 (2019): 65–78.

[394] K. Polyak and R. A. Weinberg, “Transitions Between Epithelial and Mesenchymal States: Acquisition of Malignant and Stem Cell Traits,” Nature Reviews Cancer 9, no. 4 (2009): 265–273.

[395] C. H. June, R. S. O'Connor, O. U. Kawalekar, S. Ghassemi, and M. C. Milone, “CAR T Cell Immunotherapy for Human Cancer,” Science 359, no. 6382 (2018): 1361–1365.

[396] R. Duan, W. Du, and W. Guo, “EZH2: A Novel Target for Cancer Treatment,” Journal of Hematology & Oncology 13, no. 1 (2020): 104.

[397] S. H. Lee, Y. Li, H. Kim, S. Eum, K. Park, and C. H. Lee, “The Role of EZH1 and EZH2 in Development and Cancer,” BMB Reports 55, no. 12 (2022): 595–601.

[398] X. Xiong, Y. Liu, Y. Du, X. Lai, C. Si, and H. Miao, “Unveiling the Effects of GSK126 on Osteosarcoma Cells Implications for Apoptosis, Autophagy, and Cellular Migration,” Discover Oncology 16, no. 1 (2025): 245.

[399] O. Warburg, “On the Origin of Cancer Cells,” Science 123, no. 3191 (1956): 309–314.

[400] M. G. Vander Heiden, L. C. Cantley, and C. B. Thompson, “Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation,” Science 324, no. 5930 (2009): 1029–1033.

[401] K. A. Hoadley, C. Yau, T. Hinoue, et al., “Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors From 33 Types of Cancer,” Cell 173, no. 2 (2018): 291–304.e6.

[402] M. V. Liberti and J. W. Locasale, “The Warburg Effect: How Does It Benefit Cancer Cells?,” Trends in Biochemical Sciences 41, no. 3 (2016): 211–218.

[403] C. Y. Lu, V. Terry, and D. M. Thomas, “Precision Medicine: Affording the Successes of Science,” npj Precision Oncology 7, no. 1 (2023): 3.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm – Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).